More effective & durable treatments for cancer and immunological diseases
We aim to develop medicines that can positively transform patient lives
Stamford Pharmaceuticals Inc clinical trials
News & Events
Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas May 8, 2023 Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it… Read more
Stamford Pharmaceuticals Inc announces amendment and expansion of the ASN-002-003 Phase 2a Study in BCNS and sporadic BCC subjects with up to an addition 5 arms. April 14, 2023 Stamford Pharmaceuticals Inc, today announced the expansion of its ASN-002-003 Phase 2A study (NCT 04416516). The study performed in collaboration… Read more
- Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas May 8, 2023 Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it… Read more
- Stamford Pharmaceuticals Inc announces amendment and expansion of the ASN-002-003 Phase 2a Study in BCNS and sporadic BCC subjects with up to an addition 5 arms. April 14, 2023 Stamford Pharmaceuticals Inc, today announced the expansion of its ASN-002-003 Phase 2A study (NCT 04416516). The study performed in collaboration… Read more
Who we are
We are a clinical stage oncology focused company developing novel gene therapies focused on dermatological and visceral cancers.
Our Approach
Cancers are complex dynamic and adaptive diseases with the tumor micro-environment comprising many different cell types, matrix proteins and secreted molecules.
The interplay between these elements impacts the responsiveness to therapy and whether there is continued tumor survival and progression, even in the face of continued treatments. We believe that remodelling of the tumor microenvironment and taking a multi-pathway and multi-target approach offers an opportunity to significantly improving response rates and durability of response.
Pipeline: SP-002 Monotherapy and Combination Compositions
| Product | Indication | Preclinical | Phase 1 | Phase 2 | Status |
|---|---|---|---|---|---|
| SP-002: Phase 2A | Multi-lesional Basal Cell Nevus Syndrome | On-going and to complete in 2023 | |||
| SP-002: Phase 2B | Locally Advanced BCC | Commence in 2H, 2023 | |||
| SP-002: Phase 1/2A | Squamous Cell Carcinoma | Commence in 1H, 2024 | |||
| SP-002: Phase 1/2A | Cutaneous Breast Cancer | Commence in 1H, 2024 | |||
| SP-105 | Optimization and Clinical Trial enabling Studies | On-going IND enabling Studies | |||
Our Disease Focus
Basal Cell Carcinoma
Locally Advanced Basal Cell Carcinoma and Basal Cell Nevus Syndrome are orphan Basal Cell Carcinoma indications.
Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (cSCC), is the second most common form of non-melanoma skin cancer (NMSC) comprising around 20% of all NMSC in the United States, with over 200,000 new cases each year.
Cutaneous Breast Cancer
Breast cancer is the most common cancer affecting women, with more than 1.2 million diagnosed cases worldwide annually. It is the second most common cancer after melanoma to metastasize to skin.